Zambia has a population approaching 22 million in 2025, with a median age below 19 years. The Zambia healthcare system operates through a tiered public network from rural health posts to tertiary teaching hospitals. For pharmaceutical companies, clinical research organisations, and global health funders, Zambia has high disease burden, an expanding national health insurance programme, and one of the continent's most established electronic health record systems. How the system is structured, and where data gaps remain, matters for anyone planning market entry, trial site selection, or public health investment.
Zambia's Healthcare System at a Glance
Zambia's health indicators have improved steadily over the past two decades but still trail regional benchmarks. Life expectancy at birth reached approximately 65 years in 2024, up from below 50 years in the early 2000s, largely driven by scaled-up antiretroviral therapy for HIV. The maternal mortality ratio stood at 135 per 100,000 live births as of 2020 World Bank estimates, placing Zambia in the middle range among southern African nations.
The country allocates roughly 3.3 percent of GDP to health expenditure (2023), which translates to limited per-capita spending compared to peers like South Africa or Kenya. The National Health Strategic Plan 2022-2026 governs the sector, targeting maternal mortality below 100 per 100,000 and setting 30 programme-specific goals across 27 intervention areas. It feeds into the Eighth National Development Plan (8NDP) and Zambia's longer-term Vision 2030, which targets UHC and middle-income status. In December 2025, Zambia signed a National Health Compact with the World Bank committing to recruit 74,000 health workers and expand primary care over five years.
Zambia's health workforce faces a well-documented shortage. The Ministry of Health has identified a significant health workforce gap, with the country having fewer than one doctor per 10,000 people and fewer than one nurse per 10,000 people — well below WHO-recommended thresholds. This shortage shapes everything from rural access to clinical trial feasibility.
Health System Structure and Governance
The Ministry of Health oversees all public healthcare delivery through a four-tier structure:
- Health posts and community health centres — first point of contact in rural areas, staffed primarily by community health workers and clinical officers
- First-level (district) hospitals — 99 facilities providing basic inpatient and surgical services
- Second-level (provincial/general) hospitals — 34 facilities offering specialist services and referral care
- Third-level (tertiary) hospitals — eight facilities, including the University Teaching Hospital (UTH) in Lusaka, which operates approximately 1,655 beds and handles around 400,000 outpatient visits annually
In total, Zambia maintains over 2,900 public health facilities, including 1,839 health centres and 953 health posts. Private and faith-based providers — particularly the Churches Health Association of Zambia (CHAZ) — fill gaps in rural areas where government facilities are stretched thin.
The Zambia Medicines Regulatory Authority (ZAMRA), established under the Medicines and Allied Substances Act of 2013, oversees drug registration, pharmacovigilance, and the regulatory framework for clinical trials. ZAMRA uses three review pathways: verification (for WHO-prequalified or stringent-authority-approved products), abridged, and full review. Median approval timelines improved from 727 days in 2020 to 619 days in 2023, though this still presents planning considerations for market entry.
Health Financing and NHIMA
Zambia launched the National Health Insurance Management Authority (NHIMA) in 2019 under the National Health Insurance Act of 2018. The scheme is the country's biggest health financing reform in decades, aimed at reducing out-of-pocket spending and expanding access for formal and informal sector workers.
By November 2024, NHIMA had registered over 3.4 million members, with total members and beneficiaries reaching approximately 4.6 million. The contribution structure averages around 50 Zambian Kwacha per month for a family of seven, one of the lowest-cost national health insurance programmes on the continent.
NHIMA has accredited 452 healthcare facilities as of late 2024, including both public and private providers. However, accreditation in rural areas has lagged behind urban centres, creating geographical disparities in where insured members can access care.
The government has signalled further reforms to strengthen financial sustainability, including broadening public-private engagement and increasing Treasury appropriations to subsidise coverage for vulnerable populations. Other countries in the region are running similar experiments with mandatory insurance models.
Disease Burden and Health Outcomes
Zambia's disease profile is dominated by three conditions: HIV/AIDS, malaria, and tuberculosis.
HIV is the biggest public health challenge. The 2021 Zambia Population-based HIV Impact Assessment (ZAMPHIA) reported an estimated prevalence of 11 percent among adults aged 15 and older, with women carrying a disproportionate burden at 13.9 percent. Zambia has made strong progress on treatment coverage — approximately 89 percent of adolescents living with HIV are on antiretroviral therapy. However, gaps persist in paediatric diagnosis and viral load suppression.
Malaria affects the entire population, with Zambia ranked among the 20 countries with the highest malaria incidence globally. The WHO estimated that Zambia carried 1.4 percent of global malaria cases and 1.4 percent of malaria deaths in 2023. An estimated 20,000 malaria cases occur daily, and roughly one in five children under age five is infected with malaria parasites.
Tuberculosis is closely tied to HIV. Co-infection rates remain high, and case detection has historically lagged behind actual prevalence, a gap that ongoing diagnostic studies are working to close.
Non-communicable diseases, including diabetes, cardiovascular disease, and cancer, are rising as the population ages and diets change. The Cancer Diseases Hospital in Lusaka, one of UTH's associated facilities, serves as the national referral centre for oncology.
Digital Health and EMR Adoption
Zambia has one of the more mature national electronic health record programmes in sub-Saharan Africa. SmartCare, first introduced in 2004 by the Ministry of Health in collaboration with the US Centers for Disease Control and Prevention (CDC), was originally designed to capture individual-level HIV patient data.
Since 2017, SmartCare has been adopted as the national EHR system, with support from CDC and multiple implementing partners. The system has evolved through three generations — SmartCare Legacy, SmartCare Plus, and the current SmartCare Pro — each expanding functionality and interoperability.
SmartCare Pro is now being rolled out across the country's health facility network. In Eastern Province alone, coverage has reached 61 percent of over 420 facilities as of 2025. The system captures data across maternal and child health, HIV/AIDS, tuberculosis, and malaria programmes, and reports can be generated at facility, district, provincial, and national levels.
The Centre for Infectious Disease Research in Zambia (CIDRZ) has partnered with the Ministry of Health to develop Differentiated Service Delivery reports using SmartCare data, showing how EMR infrastructure can feed directly into programme management. For organisations like Kapsule that work with structured health data across African markets, Zambia's SmartCare deployment represents one of the more advanced national-scale EMR implementations on the continent.
The SMART Zambia Institute, a government body focused on e-governance, coordinates the broader digital transformation agenda, including health facility digitisation and data standardisation efforts.
Clinical Research and Trial Activity
Zambia has a growing clinical research ecosystem, anchored by institutions with deep experience in infectious disease studies. CIDRZ alone has completed over 80 research studies, with 133 ongoing and 21 multi-centre trials as of recent reporting.
Key areas of trial activity include:
- HIV treatment and prevention — Zambia has participated in major multi-site studies, including the COVID-19 Prevention Network (CoVPN) 3008 efficacy study and research on dolutegravir-based ART transitions
- TB vaccines and diagnostics — CIDRZ is participating in Phase 3 trials for the M72/AS01E TB vaccine candidate, a Gates Medical Research Institute study with sites across five countries. A separate TB diagnostic evaluation is underway at the Chawama Clinical Research Site
- Malaria elimination — community-randomised controlled trials testing focal mass drug administration strategies in Southern Province
The National Health Research Authority (NHRA) provides ethical oversight for human subjects research, while ZAMRA handles the regulatory dimensions of clinical trial conduct. This dual-authority model is standard across the region, though coordination between the two bodies continues to evolve. For a broader view of how African nations are building clinical trial capacity, see our analysis of clinical trials in Africa.
The University of Zambia School of Medicine and UTH serve as primary academic partners for international research collaborations, with affiliations including Yale University and Vanderbilt University Medical Center.
Opportunities for Data-Driven Health Development
Zambia has a scaled national EMR system, a growing insurance programme generating claims data, and active clinical research infrastructure. What that adds up to in practice: SmartCare's national footprint generates individual-level records across multiple disease areas, a longitudinal data asset that few African countries can match at scale. NHIMA's expansion is producing structured claims and utilisation data useful for market sizing and health economic analysis. High disease burden in HIV, malaria, and TB sustains demand for epidemiological research and real-world evidence generation. And regulatory improvements at ZAMRA are shortening approval timelines, making Zambia increasingly viable for pharmaceutical market entry.
The gaps are equally clear. Rural health facilities remain under-digitised, health workforce shortages constrain data quality at the point of care, and interoperability between SmartCare, NHIMA systems, and research databases is still a work in progress.
For organisations working across African health systems, Zambia is a market where digital health infrastructure is ahead of many peers, but where turning raw data into something useful still requires structured partnerships. Kapsule's work in aggregating and standardising de-identified health records across multiple African markets provides a framework for how Zambian health data could be made accessible for clinical planning, market assessment, and public health research.
Kapsule provides access to structured, de-identified health records from over three million patient encounters across East and West Africa, with standing ethics approvals in Rwanda, Kenya, Uganda, Nigeria, and Ghana. Contact our team to discuss how Zambian health data can support your clinical trial planning, market assessment, or public health research.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.